Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No traceable primary human plasma-PK figure. The widely-quoted '2-5 min' / '2-3 min' plasma half-life could NOT be traced to a primary source and should be treated as unverified. The one primary source found (rat forebrain basal-nuclei membrane biodegradation study, Russ J Bioorg Chem / PubMed 15344653) reports a half-life >1 h in the PRESENCE of plasma membranes, with dipeptidylaminopeptidases as the main degrading enzymes, this is a tissue-membrane assay, not systemic plasma clearance. A frequently-cited intranasal-rat kinetic claim (brain Tmax ~30 min, hippocampal persistence 24 h+) traces to a single non-replicated Russian study not independently retrieved here.
No primary-sourced microgram dose obtained. Russian registered product is a 0.1% intranasal solution; specific per-dose microgram values circulating online are vendor/community-derived, not independently verified here. Route is intranasal in nearly all clinical/research use.
Decades of Russian clinical use but the peer-reviewed Western PK/efficacy literature is thin and much of it traces to the single Institute of Molecular Genetics (RAS) research lineage. Little independent replication or blinded Western trial data.
Lyophilised: General peptide handling convention: store lyophilized powder at -20 C, protect from light/moisture (compound-specific stability data not sourced).
Reconstituted: General convention: refrigerate 2-8 C after reconstitution (compound-specific stability data not sourced).
Human safety data derives almost entirely from Russian use; no Western regulatory safety review. Not FDA/EMA evaluated. Intranasal route assumed for all figures.